Dequan Pharmaceutical (Jiangsu) Co., Ltd., formerly known as Yongxin Pharmaceutical Industry (Kunshan) Co., Ltd., is a subsidiary of Yongxin Pharmaceutical Group. It was founded in December 1994, and was divided into an independent company from Yongxin Pharmaceutical Group in June 2022. It was renamed Dequan Pharmaceutical (Jiangsu) Co., Ltd. to improve local chemical services and deeply cultivate the local market. The factory covers an area of 150 mu, mainly producing and selling tablets, hard capsules Cream, small volume injection.
The company passed the national GMP certification in May 1999 and the FDA certification in the United States in 2009. At present, the annual production capacity can reach 350 million tablets, 520 million hard capsules, 6.25 million creams and 30 million injections.
At present, it mainly focuses on chemical preparations, and will continue to develop into raw materials, chemical intermediates, cosmetics, health food and other related fields in the future.
The company has always been committed to the development and research of new products, and has invested a lot of manpower and funds for this purpose. It has successively obtained more than ten product approvals, and has passed the consistency evaluation of two products. The following products have formed large-scale production and are sold nationwide.
1、Diclofenac Sodium Enteric Capsules (fēiyán)
2、Triamcinolone Acetonide and Econazole Cream (yìfùqīng)
3、Aspirin Enteric Capsules (bójī)
4、Doxycycline Hydrochloride Enteric Capsules (yǒngxǐ)
5、Valsartan Capsules (jiāfēi)
6、Ketorolac Trometamol Injection (kēduō)
7、Ketorolac Tromethamine Tablets (kēduō)
8、Valaciclovir Hydrochloride Tablets (kèbāo)
9、Metformin Hydrochloride and Glipizide Tablets (tánglìlǎng)
The company was founded in December 1994, passed the national GMP certification inspection in May 1999, and the solid preparation production line passed the FDA inspection and certification in 2009. Now it has a production line of tablets, hard capsules, creams and injections, with a production capacity of 350 million tablets, 520 million hard capsules, 6.25 million creams and 30 million injections. With excellent quality assurance and reasonable settlement price, the company has been recognized and praised by the entrusted processing party.
Now we are looking for partners in the pharmaceutical industry to provide MAH product commissioned production and undertake the commissioned production of drug marketing license holders. We welcome interested manufacturers to contact us.
The R&D Department of Dequan Pharmaceutical (Jiangsu) Co., Ltd. was rated as "Suzhou Foreign R&D Institution" and "Kunshan Science and Technology R&D Center". It consists of pharmaceutical chemistry, pharmaceutical preparations, pharmaceutical analysis and products departments, equipped with a large number of advanced imported instruments, and has various capabilities such as synthesis, processing process development, quality standard research and new drug approval.
